UP!
| 2015-08-21 | Reiterated Rating | Jefferies Group | Hold | $58.00 to $60.00 |
| 2015-08-21 | Reiterated Rating | Canaccord Genuity | Hold | $65.00 to $67.00 |
| 2015-08-20 | Reiterated Rating | William Blair | Outperform | |
| 2015-08-20 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-07-27 | Reiterated Rating | Canaccord Genuity | Hold | $65.00 |
| 2015-06-05 | Reiterated Rating | Canaccord Genuity | Hold | $62.00 to $65.00 |
| 2015-06-05 | Lower Price Target | Jefferies Group | Hold | $75.00 to $58.00 |
| 2015-06-05 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-03-06 | Downgrade | Jefferies Group | Buy to Hold | $83.00 to $75.00 |
| 2015-02-27 | Boost Price Target | Jefferies Group | Buy | $70.00 to $83.00 |
| 2015-02-27 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-02-27 | Boost Price Target | Canaccord Genuity | Hold | $52.00 to $62.00 |
| 2015-02-26 | Downgrade | Sidoti | Buy to Neutral | |
| 2014-11-21 | Downgrade | Sterne Agee CRT | Buy to Neutral | |
| 2014-08-22 | Reiterated Rating | Citigroup Inc. | Buy | $70.00 to $67.00 |
| 2014-08-22 | Downgrade | Canaccord Genuity | Buy to Hold | $63.00 to $52.00 |
| 2014-06-24 | Initiated Coverage | Sterne Agee CRT | In-Line to Buy | $65.00 |
| 2014-06-10 | Reiterated Rating | Jefferies Group | Buy | $80.00 to $70.00 |
| 2014-06-05 | Lower Price Target | Canaccord Genuity | Buy | $73.00 to $63.00 |
| 2014-06-05 | Reiterated Rating | Citigroup Inc. | Buy | $85.00 to $70.00 |
| 2014-04-24 | Initiated Coverage | BTIG Research | Neutral | |
| 2014-02-21 | Reiterated Rating | Citigroup Inc. | Buy | $80.00 to $85.00 |
| 2013-12-06 | Reiterated Rating | Citigroup Inc. | Buy | $71.00 to $80.00 |
| 2013-12-06 | Boost Price Target | Canaccord Genuity | Buy | $70.00 to $73.00 |
| 2013-11-22 | Boost Price Target | Jefferies Group | $60.00 to $80.00 | |
| 2013-11-22 | Boost Price Target | Canaccord Genuity | Buy | $57.00 to $70.00 |
| 2013-11-18 | Initiated Coverage | Citigroup Inc. | Buy | $71.00 |
| 2013-06-06 | Upgrade | Northland Capital | Under Perform to Market Perform | $40 to $44 |
| 2012-09-26 | Reiterated | WBB Securities | Strong Buy | $60 |
| 2012-08-09 | Initiated | William Blair | Outperform | |
| 2012-01-03 | Upgrade | Kaufman Bros | Hold to Buy | $28 to $38 |
| 2011-06-03 | Upgrade | WBB Securities | Buy to Strong Buy | |
| 2011-06-03 | Reiterated | Canaccord Genuity | Hold | $30.50 to $26.50 |
| 2011-01-31 | Reiterated | WBB Securities | Buy | $22 to $38 |
| 2011-01-04 | Initiated | Jefferies | Buy | $37 |
| 2010-07-20 | Initiated | Dougherty & Company | Buy | $29 |
| 2010-02-19 | Downgrade | WBB Securities | Strong Buy to Buy | $17.50 to $22 |
| 2009-12-01 | Initiated | Robert W. Baird | Neutral | $17 |
| 2015-08-21 | Reiterated Rating | Jefferies Group | Hold | $58.00 to $60.00 |
| 2015-08-21 | Reiterated Rating | Canaccord Genuity | Hold | $65.00 to $67.00 |
| 2015-08-20 | Reiterated Rating | William Blair | Outperform | |
| 2015-08-20 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-07-27 | Reiterated Rating | Canaccord Genuity | Hold | $65.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CYBX 185 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 6.41M |
| PRIMECAP MANAGEMENT CO/CA/ | 4.58M |
| HARRIS ASSOCIATES L P | 3.59M |
| STATE STREET CORP | 2.56M |
| EMINENCE CAPITAL, LP | 2.09M |
| Redmile Group, LLC | 1.54M |
| Sachem Head Capital Management LP | 1.53M |
| Vanguard Group, Inc | 1.37M |
| BlackRock Fund Advisors | 1.29M |
| Hawk Ridge Management LLC | 1.28M |
| OPPENHEIMER FUNDS INC | 1.23M |
| DIMENSIONAL FUND ADVISORS LP | 1.03M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.98M |
| UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 0.96M |
| BlackRock Institutional Trust Company, N.A. | 0.95M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Verratti Mark VP Global Sales | 0.21% (54663) | CYBX / MYGN / |
| Olin Bryan D VP Clinical Quality Regulatory | 0.20% (53424) | CYBX / |
| SIMPSON RANDAL L VP Operations | 0.16% (43669) | CYBX / |
| KenKnight Bruce H VP, Emerging Therapies | 0.14% (38519) | CYBX / |
| ROSENTHAL ARTHUR L | 0.12% (31076) | CYBX / |
| Perkins Sherrie L VP, Mktg & NBD | 0.09% (24161) | CYBX / |
| Morris Milton Mayo SR VP Research & Development | 0.08% (21146) | CYBX / |
UM